APO Research
Talk to an analyst

APO RESEARCH · REPORT

Adalimumab Injection

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Adalimumab Injection Market Outlook and Growth Opportunities 2026

22 December 2025199 pages

Choose your research edition.

Industry ResearchAdalimumab Injection Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Adalimumab Injection Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Adalimumab Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Adalimumab Injection Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Adalimumab Injection Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Adalimumab Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Adalimumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Adalimumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Adalimumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Adalimumab Injection market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Adalimumab Injection market include Jiangsu Chia Tai-Tianqing Pharmaceutical, Innovent Biologics, Sandoz, Mylan, Hisun Biopharmaceutical, Shanghai Henlius Biotech, Fresenius Kabi, Bio-Thera Solutions, Ltd. and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Adalimumab Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Adalimumab Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Adalimumab Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Adalimumab Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Adalimumab Injection Segment by Company

Jiangsu Chia Tai-Tianqing Pharmaceutical

Innovent Biologics

Sandoz

Mylan

Hisun Biopharmaceutical

Shanghai Henlius Biotech

Fresenius Kabi

Bio-Thera Solutions, Ltd.

Amgen

AbbVie

Zydus Group

Celltrion

Cadila Pharmaceuticals

Boehringer Ingelheim

Biogen

Adalimumab Injection Segment by Type

40mg/0.8ml

20mg/0.4ml

Adalimumab Injection Segment by Application

Hospitals

Clinics

Others

Adalimumab Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Adalimumab Injection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Adalimumab Injection market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Adalimumab Injection significant trends, drivers, influence factors in global and regions.

6. To analyze Adalimumab Injection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adalimumab Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Adalimumab Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adalimumab Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Adalimumab Injection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Adalimumab Injection industry.

Chapter 3: Detailed analysis of Adalimumab Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Adalimumab Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Adalimumab Injection in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Adalimumab Injection Industry Trends Table 2. Adalimumab Injection Industry Drivers Table 3. Adalimumab Injection Industry Opportunities and Challenges Table 4. Adalimumab Injection Industry Restraints Table 5. Global Adalimumab Injection Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Adalimumab Injection Revenue Share by Company (2021-2026) Table 7. Global Adalimumab Injection Sales Volume by Company (k units) & (2021-2026) Table 8. Global Adalimumab Injection Sales Volume Share by Company (2021-2026) Table 9. Global Adalimumab Injection Average Price (US$/unit) of Company (2021-2026) Table 10. Global Adalimumab Injection Company Ranking, (2024-2026) & (USD Million) Table 11. Global Adalimumab Injection Key Company Manufacturing Base & Headquarters Table 12. Global Adalimumab Injection Company, Product Type & Application Table 13. Global Adalimumab Injection Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Adalimumab Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 40mg/0.8ml Table 18. Significant Companies of 20mg/0.4ml Table 19. Global Adalimumab Injection Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Adalimumab Injection Sales Volume by Type (2021-2026) & (k units) Table 21. Global Adalimumab Injection Sales Volume by Type (2027-2032) & (k units) Table 22. Global Adalimumab Injection Sales Volume Share by Type (2021-2026) Table 23. Global Adalimumab Injection Sales Volume Share by Type (2027-2032) Table 24. Global Adalimumab Injection Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Adalimumab Injection Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Adalimumab Injection Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Adalimumab Injection Sales Value Share by Type (2021-2026) Table 28. Global Adalimumab Injection Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospitals Table 30. Significant Companies of Clinics Table 31. Significant Companies of Others Table 32. Global Adalimumab Injection Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Adalimumab Injection Sales Volume by Application (2021-2026) & (k units) Table 34. Global Adalimumab Injection Sales Volume by Application (2027-2032) & (k units) Table 35. Global Adalimumab Injection Sales Volume Share by Application (2021-2026) Table 36. Global Adalimumab Injection Sales Volume Share by Application (2027-2032) Table 37. Global Adalimumab Injection Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Adalimumab Injection Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Adalimumab Injection Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Adalimumab Injection Sales Value Share by Application (2021-2026) Table 41. Global Adalimumab Injection Sales Value Share by Application (2027-2032) Table 42. Global Adalimumab Injection Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Adalimumab Injection Sales by Region (2021-2026) & (k units) Table 44. Global Adalimumab Injection Sales Market Share by Region (2021-2026) Table 45. Global Adalimumab Injection Sales by Region (2027-2032) & (k units) Table 46. Global Adalimumab Injection Sales Market Share by Region (2027-2032) Table 47. Global Adalimumab Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Adalimumab Injection Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Adalimumab Injection Sales Value Share by Region (2021-2026) Table 50. Global Adalimumab Injection Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Adalimumab Injection Sales Value Share by Region (2027-2032) Table 52. Global Adalimumab Injection Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Adalimumab Injection Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Adalimumab Injection Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Adalimumab Injection Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Adalimumab Injection Sales by Country (2021-2026) & (k units) Table 57. Global Adalimumab Injection Sales Market Share by Country (2021-2026) Table 58. Global Adalimumab Injection Sales by Country (2027-2032) & (k units) Table 59. Global Adalimumab Injection Sales Market Share by Country (2027-2032) Table 60. Global Adalimumab Injection Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Adalimumab Injection Sales Value Market Share by Country (2021-2026) Table 62. Global Adalimumab Injection Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Adalimumab Injection Sales Value Market Share by Country (2027-2032) Table 64. Jiangsu Chia Tai-Tianqing Pharmaceutical Company Information Table 65. Jiangsu Chia Tai-Tianqing Pharmaceutical Business Overview Table 66. Jiangsu Chia Tai-Tianqing Pharmaceutical Adalimumab Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Jiangsu Chia Tai-Tianqing Pharmaceutical Adalimumab Injection Product Portfolio Table 68. Jiangsu Chia Tai-Tianqing Pharmaceutical Recent Development Table 69. Innovent Biologics Company Information Table 70. Innovent Biologics Business Overview Table 71. Innovent Biologics Adalimumab Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Innovent Biologics Adalimumab Injection Product Portfolio Table 73. Innovent Biologics Recent Development Table 74. Sandoz Company Information Table 75. Sandoz Business Overview Table 76. Sandoz Adalimumab Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Sandoz Adalimumab Injection Product Portfolio Table 78. Sandoz Recent Development Table 79. Mylan Company Information Table 80. Mylan Business Overview Table 81. Mylan Adalimumab Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Mylan Adalimumab Injection Product Portfolio Table 83. Mylan Recent Development Table 84. Hisun Biopharmaceutical Company Information Table 85. Hisun Biopharmaceutical Business Overview Table 86. Hisun Biopharmaceutical Adalimumab Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Hisun Biopharmaceutical Adalimumab Injection Product Portfolio Table 88. Hisun Biopharmaceutical Recent Development Table 89. Shanghai Henlius Biotech Company Information Table 90. Shanghai Henlius Biotech Business Overview Table 91. Shanghai Henlius Biotech Adalimumab Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Shanghai Henlius Biotech Adalimumab Injection Product Portfolio Table 93. Shanghai Henlius Biotech Recent Development Table 94. Fresenius Kabi Company Information Table 95. Fresenius Kabi Business Overview Table 96. Fresenius Kabi Adalimumab Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Fresenius Kabi Adalimumab Injection Product Portfolio Table 98. Fresenius Kabi Recent Development Table 99. Bio-Thera Solutions, Ltd. Company Information Table 100. Bio-Thera Solutions, Ltd. Business Overview Table 101. Bio-Thera Solutions, Ltd. Adalimumab Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Bio-Thera Solutions, Ltd. Adalimumab Injection Product Portfolio Table 103. Bio-Thera Solutions, Ltd. Recent Development Table 104. Amgen Company Information Table 105. Amgen Business Overview Table 106. Amgen Adalimumab Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Amgen Adalimumab Injection Product Portfolio Table 108. Amgen Recent Development Table 109. AbbVie Company Information Table 110. AbbVie Business Overview Table 111. AbbVie Adalimumab Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. AbbVie Adalimumab Injection Product Portfolio Table 113. AbbVie Recent Development Table 114. Zydus Group Company Information Table 115. Zydus Group Business Overview Table 116. Zydus Group Adalimumab Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Zydus Group Adalimumab Injection Product Portfolio Table 118. Zydus Group Recent Development Table 119. Celltrion Company Information Table 120. Celltrion Business Overview Table 121. Celltrion Adalimumab Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Celltrion Adalimumab Injection Product Portfolio Table 123. Celltrion Recent Development Table 124. Cadila Pharmaceuticals Company Information Table 125. Cadila Pharmaceuticals Business Overview Table 126. Cadila Pharmaceuticals Adalimumab Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Cadila Pharmaceuticals Adalimumab Injection Product Portfolio Table 128. Cadila Pharmaceuticals Recent Development Table 129. Boehringer Ingelheim Company Information Table 130. Boehringer Ingelheim Business Overview Table 131. Boehringer Ingelheim Adalimumab Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. Boehringer Ingelheim Adalimumab Injection Product Portfolio Table 133. Boehringer Ingelheim Recent Development Table 134. Biogen Company Information Table 135. Biogen Business Overview Table 136. Biogen Adalimumab Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Biogen Adalimumab Injection Product Portfolio Table 138. Biogen Recent Development Table 139. Key Raw Materials Table 140. Raw Materials Key Suppliers Table 141. Adalimumab Injection Distributors List Table 142. Adalimumab Injection Customers List Table 143. Research Programs/Design for This Report Table 144. Authors List of This Report Table 145. Secondary Sources Table 146. Primary Sources List of Figures Figure 1. Adalimumab Injection Product Image Figure 2. Global Adalimumab Injection Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Adalimumab Injection Sales Value (2021-2032) & (US$ Million) Figure 4. Global Adalimumab Injection Sales (2021-2032) & (k units) Figure 5. Global Adalimumab Injection Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Adalimumab Injection Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 40mg/0.8ml Image Figure 10. 20mg/0.4ml Image Figure 11. Global Adalimumab Injection Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Adalimumab Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Adalimumab Injection Sales Volume Share by Type (2021-2032) Figure 14. Global Adalimumab Injection Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Adalimumab Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Adalimumab Injection Sales Value Share by Type (2021-2032) Figure 17. Hospitals Image Figure 18. Clinics Image Figure 19. Others Image Figure 20. Global Adalimumab Injection Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Adalimumab Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Adalimumab Injection Sales Volume Share by Application (2021-2032) Figure 23. Global Adalimumab Injection Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Adalimumab Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Adalimumab Injection Sales Value Share by Application (2021-2032) Figure 26. Global Adalimumab Injection Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Adalimumab Injection Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Adalimumab Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Adalimumab Injection Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Adalimumab Injection Sales Value (2021-2032) & (US$ Million) Figure 31. North America Adalimumab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Adalimumab Injection Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Adalimumab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Adalimumab Injection Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Adalimumab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Adalimumab Injection Sales Value (2021-2032) & (US$ Million) Figure 37. South America Adalimumab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Adalimumab Injection Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Adalimumab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Adalimumab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Adalimumab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Adalimumab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Adalimumab Injection Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Adalimumab Injection Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • 40mg/0.8ml
  • 20mg/0.4ml
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Jiangsu Chia Tai-Tianqing Pharmaceutical
  • Innovent Biologics
  • Sandoz
  • Mylan
  • Hisun Biopharmaceutical
  • Shanghai Henlius Biotech
  • Fresenius Kabi
  • Bio-Thera Solutions, Ltd.
  • Amgen
  • AbbVie
  • Zydus Group
  • Celltrion
  • Cadila Pharmaceuticals
  • Boehringer Ingelheim
  • Biogen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Adalimumab Injection Sales Value (2021-2032)
  4. 1.2.2 Global Adalimumab Injection Sales Volume (2021-2032)
  5. 1.2.3 Global Adalimumab Injection Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Adalimumab Injection Market Dynamics
  1. 2.1 Adalimumab Injection Industry Trends
  2. 2.2 Adalimumab Injection Industry Drivers
  3. 2.3 Adalimumab Injection Industry Opportunities and Challenges
  4. 2.4 Adalimumab Injection Industry Restraints
3 Adalimumab Injection Market by Company
  1. 3.1 Global Adalimumab Injection Company Revenue Ranking in 2025
  2. 3.2 Global Adalimumab Injection Revenue by Company (2021-2026)
  3. 3.3 Global Adalimumab Injection Sales Volume by Company (2021-2026)
  4. 3.4 Global Adalimumab Injection Average Price by Company (2021-2026)
  5. 3.5 Global Adalimumab Injection Company Ranking (2024-2026)
  6. 3.6 Global Adalimumab Injection Company Manufacturing Base and Headquarters
  7. 3.7 Global Adalimumab Injection Company Product Type and Application
  8. 3.8 Global Adalimumab Injection Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Adalimumab Injection Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Adalimumab Injection Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Adalimumab Injection Market by Type
  1. 4.1 Adalimumab Injection Type Introduction
  2. 4.1.1 40mg/0.8ml
  3. 4.1.2 20mg/0.4ml
  4. 4.2 Global Adalimumab Injection Sales Volume by Type
  5. 4.2.1 Global Adalimumab Injection Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Adalimumab Injection Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Adalimumab Injection Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Adalimumab Injection Sales Value by Type
  9. 4.3.1 Global Adalimumab Injection Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Adalimumab Injection Sales Value by Type (2021-2032)
  11. 4.3.3 Global Adalimumab Injection Sales Value Share by Type (2021-2032)
5 Adalimumab Injection Market by Application
  1. 5.1 Adalimumab Injection Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Adalimumab Injection Sales Volume by Application
  6. 5.2.1 Global Adalimumab Injection Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Adalimumab Injection Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Adalimumab Injection Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Adalimumab Injection Sales Value by Application
  10. 5.3.1 Global Adalimumab Injection Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Adalimumab Injection Sales Value by Application (2021-2032)
  12. 5.3.3 Global Adalimumab Injection Sales Value Share by Application (2021-2032)
6 Adalimumab Injection Regional Sales and Value Analysis
  1. 6.1 Global Adalimumab Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Adalimumab Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Adalimumab Injection Sales by Region: 2021-2026
  4. 6.2.2 Global Adalimumab Injection Sales by Region (2027-2032)
  5. 6.3 Global Adalimumab Injection Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Adalimumab Injection Sales Value by Region (2021-2032)
  7. 6.4.1 Global Adalimumab Injection Sales Value by Region: 2021-2026
  8. 6.4.2 Global Adalimumab Injection Sales Value by Region (2027-2032)
  9. 6.5 Global Adalimumab Injection Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Adalimumab Injection Sales Value (2021-2032)
  12. 6.6.2 North America Adalimumab Injection Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Adalimumab Injection Sales Value (2021-2032)
  15. 6.7.2 Europe Adalimumab Injection Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Adalimumab Injection Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Adalimumab Injection Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Adalimumab Injection Sales Value (2021-2032)
  21. 6.9.2 South America Adalimumab Injection Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Adalimumab Injection Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Adalimumab Injection Sales Value Share by Country, 2025 VS 2032
7 Adalimumab Injection Country-level Sales and Value Analysis
  1. 7.1 Global Adalimumab Injection Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Adalimumab Injection Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Adalimumab Injection Sales by Country (2021-2032)
  4. 7.3.1 Global Adalimumab Injection Sales by Country (2021-2026)
  5. 7.3.2 Global Adalimumab Injection Sales by Country (2027-2032)
  6. 7.4 Global Adalimumab Injection Sales Value by Country (2021-2032)
  7. 7.4.1 Global Adalimumab Injection Sales Value by Country (2021-2026)
  8. 7.4.2 Global Adalimumab Injection Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Adalimumab Injection Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Adalimumab Injection Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Adalimumab Injection Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Adalimumab Injection Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Adalimumab Injection Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Adalimumab Injection Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Adalimumab Injection Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Adalimumab Injection Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Adalimumab Injection Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Adalimumab Injection Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Adalimumab Injection Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Adalimumab Injection Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Adalimumab Injection Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Adalimumab Injection Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Adalimumab Injection Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Adalimumab Injection Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Adalimumab Injection Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Adalimumab Injection Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Adalimumab Injection Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Adalimumab Injection Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Adalimumab Injection Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Adalimumab Injection Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Adalimumab Injection Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Adalimumab Injection Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Adalimumab Injection Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Adalimumab Injection Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Adalimumab Injection Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Adalimumab Injection Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Adalimumab Injection Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Adalimumab Injection Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Jiangsu Chia Tai-Tianqing Pharmaceutical
  2. 8.1.1 Jiangsu Chia Tai-Tianqing Pharmaceutical Company Information
  3. 8.1.2 Jiangsu Chia Tai-Tianqing Pharmaceutical Business Overview
  4. 8.1.3 Jiangsu Chia Tai-Tianqing Pharmaceutical Adalimumab Injection Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Jiangsu Chia Tai-Tianqing Pharmaceutical Adalimumab Injection Product Portfolio
  6. 8.1.5 Jiangsu Chia Tai-Tianqing Pharmaceutical Recent Developments
  7. 8.2 Innovent Biologics
  8. 8.2.1 Innovent Biologics Company Information
  9. 8.2.2 Innovent Biologics Business Overview
  10. 8.2.3 Innovent Biologics Adalimumab Injection Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Innovent Biologics Adalimumab Injection Product Portfolio
  12. 8.2.5 Innovent Biologics Recent Developments
  13. 8.3 Sandoz
  14. 8.3.1 Sandoz Company Information
  15. 8.3.2 Sandoz Business Overview
  16. 8.3.3 Sandoz Adalimumab Injection Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sandoz Adalimumab Injection Product Portfolio
  18. 8.3.5 Sandoz Recent Developments
  19. 8.4 Mylan
  20. 8.4.1 Mylan Company Information
  21. 8.4.2 Mylan Business Overview
  22. 8.4.3 Mylan Adalimumab Injection Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Mylan Adalimumab Injection Product Portfolio
  24. 8.4.5 Mylan Recent Developments
  25. 8.5 Hisun Biopharmaceutical
  26. 8.5.1 Hisun Biopharmaceutical Company Information
  27. 8.5.2 Hisun Biopharmaceutical Business Overview
  28. 8.5.3 Hisun Biopharmaceutical Adalimumab Injection Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Hisun Biopharmaceutical Adalimumab Injection Product Portfolio
  30. 8.5.5 Hisun Biopharmaceutical Recent Developments
  31. 8.6 Shanghai Henlius Biotech
  32. 8.6.1 Shanghai Henlius Biotech Company Information
  33. 8.6.2 Shanghai Henlius Biotech Business Overview
  34. 8.6.3 Shanghai Henlius Biotech Adalimumab Injection Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Shanghai Henlius Biotech Adalimumab Injection Product Portfolio
  36. 8.6.5 Shanghai Henlius Biotech Recent Developments
  37. 8.7 Fresenius Kabi
  38. 8.7.1 Fresenius Kabi Company Information
  39. 8.7.2 Fresenius Kabi Business Overview
  40. 8.7.3 Fresenius Kabi Adalimumab Injection Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Fresenius Kabi Adalimumab Injection Product Portfolio
  42. 8.7.5 Fresenius Kabi Recent Developments
  43. 8.8 Bio-Thera Solutions, Ltd.
  44. 8.8.1 Bio-Thera Solutions, Ltd. Company Information
  45. 8.8.2 Bio-Thera Solutions, Ltd. Business Overview
  46. 8.8.3 Bio-Thera Solutions, Ltd. Adalimumab Injection Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Bio-Thera Solutions, Ltd. Adalimumab Injection Product Portfolio
  48. 8.8.5 Bio-Thera Solutions, Ltd. Recent Developments
  49. 8.9 Amgen
  50. 8.9.1 Amgen Company Information
  51. 8.9.2 Amgen Business Overview
  52. 8.9.3 Amgen Adalimumab Injection Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Amgen Adalimumab Injection Product Portfolio
  54. 8.9.5 Amgen Recent Developments
  55. 8.10 AbbVie
  56. 8.10.1 AbbVie Company Information
  57. 8.10.2 AbbVie Business Overview
  58. 8.10.3 AbbVie Adalimumab Injection Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 AbbVie Adalimumab Injection Product Portfolio
  60. 8.10.5 AbbVie Recent Developments
  61. 8.11 Zydus Group
  62. 8.11.1 Zydus Group Company Information
  63. 8.11.2 Zydus Group Business Overview
  64. 8.11.3 Zydus Group Adalimumab Injection Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Zydus Group Adalimumab Injection Product Portfolio
  66. 8.11.5 Zydus Group Recent Developments
  67. 8.12 Celltrion
  68. 8.12.1 Celltrion Company Information
  69. 8.12.2 Celltrion Business Overview
  70. 8.12.3 Celltrion Adalimumab Injection Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Celltrion Adalimumab Injection Product Portfolio
  72. 8.12.5 Celltrion Recent Developments
  73. 8.13 Cadila Pharmaceuticals
  74. 8.13.1 Cadila Pharmaceuticals Company Information
  75. 8.13.2 Cadila Pharmaceuticals Business Overview
  76. 8.13.3 Cadila Pharmaceuticals Adalimumab Injection Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Cadila Pharmaceuticals Adalimumab Injection Product Portfolio
  78. 8.13.5 Cadila Pharmaceuticals Recent Developments
  79. 8.14 Boehringer Ingelheim
  80. 8.14.1 Boehringer Ingelheim Company Information
  81. 8.14.2 Boehringer Ingelheim Business Overview
  82. 8.14.3 Boehringer Ingelheim Adalimumab Injection Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Boehringer Ingelheim Adalimumab Injection Product Portfolio
  84. 8.14.5 Boehringer Ingelheim Recent Developments
  85. 8.15 Biogen
  86. 8.15.1 Biogen Company Information
  87. 8.15.2 Biogen Business Overview
  88. 8.15.3 Biogen Adalimumab Injection Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Biogen Adalimumab Injection Product Portfolio
  90. 8.15.5 Biogen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Adalimumab Injection Value Chain Analysis
  2. 9.1.1 Adalimumab Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Adalimumab Injection Sales Mode & Process
  6. 9.2 Adalimumab Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Adalimumab Injection Distributors
  9. 9.2.3 Adalimumab Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst